Prevalence of Psoriasis Alba in Psoriatic Patients

August 11, 2010 updated by: Hadassah Medical Organization
Interdigital psoriasis (psoriasis alba) is atypical and rare form of psoriasis that is often missed as it is commonly mistaken for either dermatoses or fungal infection.In this study we observed and analyzed the prevalence of psoriasis interdigital of palms and soles and brought medical awareness to dermatologists and family doctors this rare form of psoriasis. Thus, you can help to avoid mistaken diagnosis and the start of correct treatment as soon as possible.

Study Overview

Status

Unknown

Conditions

Detailed Description

Hospitalized patients and outpatient clinic will be included in the study after receiving the signature of a inform consent.Patients groups : 100 patients with psoriasis,100 patients with atopic dermatitis and 100 healthy patients (control group).Patients with atopic dermatitis will be the secondary control group.Patients diagnosed with inflammatory condition of interdigital skin of the palms and soles will be checked by fungal microscopy test.If the fungal test is negative ,we need to prepare to a biopsy of the skin in this area .Following results of the skin biopsy conclusions can be shown about the prevalence of interdigital psoriasis in psoriatic patients enabling suitable treatment to be given to the patients.

Study Type

Observational

Enrollment (Actual)

300

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

patients of dermatology depatment and outpatient clinic in the hospital

Description

Inclusion Criteria:

  • patients above 18 years old ,hebrew speakers, patients with psoriasis vulgaris or atopic dermatitis without systemic treatment

Exclusion Criteria:

  • patients below 18 years old, pregnancy women, patients treated with systemic agents for psoriasis or atopic dermatitis(methotrexate,cyclosporin,neotigason)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
3
patients with psoriasis , patients with atopic dermatitis and healthy patients.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Vera Leibovici, MD, Hadassah Medical Organization
  • Principal Investigator: Natalya Lemster, MD, Hadassah Medical Organization

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2008

Study Registration Dates

First Submitted

February 1, 2009

First Submitted That Met QC Criteria

February 2, 2009

First Posted (Estimate)

February 3, 2009

Study Record Updates

Last Update Posted (Estimate)

August 12, 2010

Last Update Submitted That Met QC Criteria

August 11, 2010

Last Verified

February 1, 2009

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IPS001-HMO-CTIL

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psoriasis

3
Subscribe